Fig. 2: Kaplan-Meier curve showing progression free survival (PFS) among 29 patients who received Pembrolizumab.
Median PFS 8.86 weeks (95% confidence interval 6.00â9.43).
Fig. 2: Kaplan-Meier curve showing progression free survival (PFS) among 29 patients who received Pembrolizumab. | British Journal of Cancer
